SCHEMBL7227753

SCHEMBL7227753

COC(=O)c1ccc(OC(C)c2coc(-c3ccccc3)n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADCY1 Q08828 1/20 0.47
PPARG P37231 3/20 0.44
PPARA Q07869 3/20 0.44
ALDH1A1 P00352 3/20 0.44
MAPT P10636 3/20 0.44
RAB9A P51151 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
HPGD P15428 2/20 0.44
NPC1 O15118 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HSD17B10 Q99714 1/20 0.44
KMT2A Q03164 3/20 0.41
ENPP3 O14638 1/20 0.41
ENPP1 P22413 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A3 P47895 1/20 0.41
GLA P06280 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TSHR P16473 1/20 0.41
DGAT1 O75907 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7154961 0.80 PPARG (0.49) ADCY1PPARGPPARAALDH1A1RAB9A
SCHEMBL7159207 0.77 PPARG (0.47) ADCY1PPARGPPARAALDH1A1MAPT
SCHEMBL7221412 0.76 ENPP3 (0.62) ALDH1A1MAPTRAB9ASMN1; SMN2HPGD
SCHEMBL29523345 0.74 LTB4R (0.57) ALDH1A1MAPTRAB9ASMN1; SMN2NPC1
SCHEMBL29035407 0.74 LTB4R (0.57) ALDH1A1MAPTRAB9ASMN1; SMN2NPC1
SCHEMBL29523814 0.74 LTB4R (0.57) ALDH1A1MAPTRAB9ASMN1; SMN2NPC1
SCHEMBL3647221 0.74 MAPT (0.57) ALDH1A1MAPTRAB9ASMN1; SMN2NPC1
SCHEMBL7227759 0.74 MAPT (0.56) PPARGPPARAMAPTRAB9ASMN1; SMN2
SCHEMBL7217142 0.73 ENPP3 (0.48) ALDH1A1MAPTRAB9ASMN1; SMN2HPGD
SCHEMBL1123238 0.73 MAPT (0.55) PPARGPPARAMAPTRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6617342-B1 Treating hyperglycemia associated with non- insulin dependant diabetes and for treating hyperlipidemia. ELI LILLY AND COMPANY 2003-09-09 US disclosed